IL-2 is a gradually proved potential therapeutic target for hepatocellular carcinoma.
School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei, China; Institute for Liver Diseases of Anhui Medical University, Anhui Medical University, Hefei, China.
Tao
T
Xu
School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei, China; Institute for Liver Diseases of Anhui Medical University, Anhui Medical University, Hefei, China.
Xiao-Ming
XM
Meng
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Hong-Wei
HW
Yao
School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei, China; Institute for Liver Diseases of Anhui Medical University, Anhui Medical University, Hefei, China. Electronic address: lj@ahmu.edu.cn.
Jun
J
Li
D000818:Animals; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology*; D006727:Hormone Antagonists / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000235:genetics*; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy*; D015735:Mifepristone / Q000008:administration & dosage*
D006727:Hormone Antagonists; D007376:Interleukin-2; D015735:Mifepristone